Humanalbumin Kedrion (Human Albumin Solution)

Humanalbumin Kedrion is employed as a plasma volume expander in clinical settings where rapid restoration of circulatory volume is required.

• Treatment of hypovolemia due to fluid loss, hemorrhage, or dehydration.
• Management of circulatory shock associated with trauma, sepsis, or anaphylaxis.
• Supportive care for patients with extensive burns to maintain intravascular oncotic pressure.
• Correction of hypoalbuminemia in liver disease, nephrotic syndrome, or malnutrition.
• Adjunct therapy during major surgery to prevent intra‑operative hypotension.
• Volume expansion in patients with severe pancreatitis to improve microcirculatory flow.
• Use in renal replacement therapy to counteract albumin loss during dialysis.

• Humanalbumin Kedrion provides exogenous albumin that increases plasma oncotic pressure by contributing to the colloid osmotic gradient. The elevated oncotic pressure draws water from the interstitial and intracellular compartments into the vascular space, thereby expanding intravascular volume. This effect supports hemodynamic stability and improves tissue perfusion without directly influencing cardiac contractility or vascular tone. The albumin molecules also bind and transport endogenous substances, contributing to overall plasma protein balance.

Adverse reactions to Humanalbumin Kedrion are generally infrequent but may occur during or after infusion, and they can range from mild, transient symptoms to rare, life‑threatening events.

Common

• Mild fever or chills.
• Transient hypotension or hypertension.
• Headache or dizziness.
• Nausea or vomiting.
• Localized erythema or urticaria at the infusion site.
• Mild pruritus or skin rash.
• Flushing or warmth sensation.
• Slight increase in serum creatinine.

Serious

• Anaphylactic or severe allergic reactions.
• Acute hemolysis.
• Pulmonary edema due to rapid volume overload.
• Thromboembolic events.
• Sepsis related to contaminated product.
• Disseminated intravascular coagulation.
• Acute renal failure secondary to volume overload.
• Cardiogenic pulmonary edema in patients with compromised cardiac function.

When using Humanalbumin Kedrion, clinicians should assess patient risk factors and monitor clinical status to minimize potential complications.

• Verify indication and ensure benefit outweighs risk of volume overload.
• Assess baseline fluid balance, cardiac function, and pulmonary status before infusion.
• Use the lowest effective volume and infuse at a controlled rate.
• Monitor vital signs, especially blood pressure and heart rate, during and after administration.
• Observe for signs of allergic reaction or anaphylaxis throughout the infusion.
• Adjust dosage in patients with renal or hepatic impairment.
• Avoid use in patients with known hypersensitivity to human albumin.

Humanalbumin Kedrion may interact with other therapies that affect fluid balance, coagulation, or immune response, requiring careful consideration.

Avoid

• Concurrent administration of other volume expanders (e.g., synthetic colloids) that may cause excessive intravascular volume.
• Use with blood products containing incompatible antibodies.
• Concurrent infusion of hypertonic saline solutions, which can cause rapid shifts in osmolarity.

Use with caution

• Diuretics, which may alter the intended volume expansion effect.
• Vasopressors, as combined therapy can affect hemodynamic stability.
• Anticoagulants, because changes in plasma protein levels can modify drug binding.
• Immunosuppressants, due to potential additive risk of infection.
• Renal replacement therapies, as albumin may be removed during dialysis, affecting dosing.
• Chemotherapeutic agents that are highly protein bound, since albumin infusion can alter their free concentrations.